Is KZIA or LGND more undervalued in 2026?

CirclFi compares Kazia Therapeutics Limited (KZIA) and Ligand Pharmaceuticals Incorpor (LGND) using 13 institutional-grade valuation models. KZIA has a Quality of Company score of 4.3/10 while LGND scores 7.8/10.

Which is a better buy — KZIA or LGND?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KZIA and LGND valuations compare?

KZIA at $12.67 and LGND at $234.66 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KZIA vs LGND Valuation Comparison 2026 — Intrinsic Value Analysis

KZIA

Biotechnology

Kazia Therapeutics Limited

Quality

4.3

out of 10

Value Trap

SAFE

Price

$12.67

Last close

Models

10/13

Active

LGND

Biotechnology

Ligand Pharmaceuticals Incorpor

Quality

7.8

out of 10

Value Trap

LOW

Price

$234.66

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KZIA Fair Value	KZIA Upside	LGND Fair Value	LGND Upside
Bayesian DCF	Intrinsic	$5.76	-54.5%	$66.47	-71.7%
Earnings Power Value	Intrinsic	—	—	$57.08	-75.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.95	-76.7%	$16.28	-93.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KZIA vs LGND — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KZIA vs LGND — Which Stock Is More Undervalued?

LGND scores higher with a 7.8/10 quality rating vs KZIA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kazia Therapeutics Limited (KZIA) and Ligand Pharmaceuticals Incorpor (LGND) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KZIA currently trades at $12.67 with a QOC of 4.3/10, while LGND trades at $234.66 with a QOC of 7.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).